Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.40 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117418 | 0.88 | ROCK2 (0.44) | ROCK2ROCK1MYLK4 | |
| SCHEMBL114017 | 0.85 | ROCK2 (0.61) | ROCK2ROCK1MYLK4 | |
| SCHEMBL116772 | 0.83 | ROCK2 (0.42) | ROCK2ROCK1 | |
| SCHEMBL2775172 | 0.78 | ROCK2 (0.57) | ROCK2ROCK1MYLK4 | |
| SCHEMBL111744 | 0.75 | ROCK2 (0.60) | ROCK2ROCK1MYLK4 | |
| SCHEMBL113527 | 0.73 | ROCK2 (0.78) | ROCK2ROCK1MYLK4 | |
| SCHEMBL2775620 | 0.73 | ROCK2 (0.57) | ROCK2ROCK1MYLK4 | |
| SCHEMBL112522 | 0.72 | ROCK2 (0.60) | ROCK2ROCK1MYLK4 | |
| SCHEMBL113472 | 0.70 | PARP1 (0.39) | ROCK2ROCK1MYLK4 | |
| SCHEMBL21774951 | 0.69 | ROCK2 (0.76) | ROCK2ROCK1MYLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424857-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | Aerie Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |